Replication Study in a Japanese Population of Six Susceptibility Loci for Type 2 Diabetes Originally Identified by a Transethnic Meta-Analysis of Genome-Wide Association Studies

We performed a replication study in a Japanese population to evaluate the association between type 2 diabetes and six susceptibility loci (TMEM154, SSR1, FAF1, POU5F1, ARL15, and MPHOSPH9) originally identified by a transethnic meta-analysis of genome-wide association studies (GWAS) in 2014. We geno...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 11; no. 4; p. e0154093
Main Authors Matsuba, Ren, Imamura, Minako, Tanaka, Yasushi, Iwata, Minoru, Hirose, Hiroshi, Kaku, Kohei, Maegawa, Hiroshi, Watada, Hirotaka, Tobe, Kazuyuki, Kashiwagi, Atsunori, Kawamori, Ryuzo, Maeda, Shiro
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 26.04.2016
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:We performed a replication study in a Japanese population to evaluate the association between type 2 diabetes and six susceptibility loci (TMEM154, SSR1, FAF1, POU5F1, ARL15, and MPHOSPH9) originally identified by a transethnic meta-analysis of genome-wide association studies (GWAS) in 2014. We genotyped 7,620 Japanese participants (5,817 type 2 diabetes patients and 1,803 controls) for each of the single nucleotide polymorphisms (SNPs) using a multiplex polymerase chain reaction invader assay. The association of each SNP locus with the disease was evaluated using logistic regression analysis. Of the six SNPs examined in this study, four (rs6813195 near TMEM154, rs17106184 in FAF1, rs3130501 in POU5F1 and rs4275659 near MPHOSPH9) had the same direction of effect as in the original reports, but two (rs9505118 in SSR1 and rs702634 in ARL15) had the opposite direction of effect. Among these loci, rs3130501 and rs4275659 were nominally associated with type 2 diabetes (rs3130501; p = 0.017, odds ratio [OR] = 1.113, 95% confidence interval [CI] 1.019-1.215, rs4275659; p = 0.012, OR = 1.127, 95% CI 1.026-1.238, adjusted for sex, age and body mass index), but we did not observe a significant association with type 2 diabetes for any of the six evaluated SNP loci in our Japanese population. Our results indicate that effects of the six SNP loci identified in the transethnic GWAS meta-analysis are not major among the Japanese, although SNPs in POU5F1 and MPHOSPH9 loci may have some effect on susceptibility to type 2 diabetes in this population.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Conceived and designed the experiments: M. Imamura SM. Performed the experiments: RM M. Imamura SM. Analyzed the data: RM M. Imamura SM. Contributed reagents/materials/analysis tools: YT M. Iwata HH KK HM HW KT AK RK. Wrote the paper: RM M. Imamura SM. Contributed to the interpretation of the data: YT M. Iwata HH KK HM HW KT AK RK.
Competing Interests: The authors have read the journal's policy and the authors of this manuscript have the following competing interests. HW is a member of advisory panel of Novo Nordisk Pharma, Sanofi, Dainippon Sumitomo Pharma, Mochida Pharmaceutical Co, MSD, Takeda Pharmaceutical Co, Boehringer Ingelheim, Ono Pharmaceutical Co., Novartis Pharmaceuticals, Mitsubishi-Tanabe Pharma, AstraZeneca, Kowa Co. Astellas Pharma Inc., Pfizer Inc., has received lecture fees from Novo Nordisk Pharma, Eli Lilly Japan, Sanofi, Dainippon Sumitomo Pharma, Fujifilm, Bayer, Kissei Phamaceutical Co., Mochida Pharmaceutical Co, MSD, Takeda Pharmaceutical Co, Boehringer Ingelheim, Daiichi Sankyo, Inc, Ono Pharmaceutical Co. Novartis Pharmaceuticals, Boehringer Ingelheim, Mitsubishi-Tanabe Pharma, AstraZeneca, Kyowa Hokko Kirin Co, Sanwa Kagaku Kenkyusho Co, Kowa Co. Astellas Pharma Inc., Pfizer Inc., and received research funds from Johnson & Johnson, Kyowa Hokko Kirin Co., Kissei Phamaceutical Co., Bristol-Myers Squibb, Novo Nordisk Pharma, Astellas Pharma Inc., MSD, Dainippon Sumitomo Pharma., AstraZeneca, Teijin Pharma, Mochida Pharmaceutical Co., Sanofi, Sanwa Kagaku Kenkyusho Co., Boehringer Ingelheim, Pfizer Inc., Novartis Pharmaceuticals, Ono Pharmaceutical Co., Mitsubishi-Tanabe Pharma, Daiichi Sankyo, Inc, Takeda Pharmaceutical Co., Eli Lilly Japan, Taisho Toyama Pharmaceutical Co. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0154093